Cargando…
Combination of BCL-2 and MYC protein expression improves high-risk stratification in diffuse large B-cell lymphoma
PURPOSE: To evaluate whether the addition of two biological markers (MYC and BCL-2 protein overexpression) improves the stratification of high-risk patients with diffuse large B-cell lymphoma (DLBCL). METHOD: Seven risk factors were identified at diagnosis, and a maximum of 7 points were assigned to...
Autores principales: | Wang, Jing, Zhou, Min, Xu, Jing-Yan, Chen, Bing, Ouyang, Jian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4583112/ https://www.ncbi.nlm.nih.gov/pubmed/26425100 http://dx.doi.org/10.2147/OTT.S86093 |
Ejemplares similares
-
A three-gene signature based on MYC, BCL-2 and NFKBIA improves risk stratification in diffuse large B-cell lymphoma
por: Derenzini, Enrico, et al.
Publicado: (2020) -
Copy Number Alteration and Mutational Profile of High-Grade B-Cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements, Diffuse Large B-Cell Lymphoma with MYC-Rearrangement, and Diffuse Large B-Cell Lymphoma with MYC-Cluster Amplification
por: Miyaoka, Masashi, et al.
Publicado: (2022) -
Diffuse Large B-Cell Lymphoma in Kenya: MYC, BCL2, and the Cell of
Origin
por: Wawire, Jonathan, et al.
Publicado: (2019) -
MYC overexpression but not MYC/BCL2 double expression predicts survival in bulky mass diffuse large B‐cell lymphoma patients
por: Wang, Yanjie, et al.
Publicado: (2023) -
MYC translocation and/or BCL 2 protein expression are associated with poor prognosis in diffuse large B‐cell lymphoma
por: Kawamoto, Keisuke, et al.
Publicado: (2016)